8-K: PharmaCyte Secures $7M Capital Raise from Existing Investors

PharmaCyte Biotech, Inc. announced a $7 million private placement of Series C convertible preferred stock and warrants, primarily from existing investors, to strengthen its balance sheet and pursue strategic alternatives.

Summary

• PharmaCyte Biotech, Inc. entered into a Securities Purchase Agreement on August 17, 2025, for a private placement expected to close on August 19, 2025.
• The company will sell 7,000 shares of newly designated Series C convertible preferred stock, with a stated value of $1,000 per share, initially convertible into up to 7,000,000 shares of common stock at an initial conversion price of $1.00.
• Warrants to purchase up to an aggregate of 7,000,000 shares of common stock will also be issued, exercisable immediately at an exercise price of $1.00 per share and expiring five years from issuance.
• The aggregate gross proceeds from the private placement are expected to be $7 million.
• The preferred stock accrues dividends at 7% per annum, compounded quarterly, payable in cash, increasing to 15% per annum upon a 'Triggering Event'.
• The company is required to file a resale registration statement for 150% of the conversion shares and warrant shares within 30 calendar days of August 17, 2025, and have it effective within 60-90 days.
• Liquidated damages of 2% of the purchase price will be paid every 30 days for registration filing, effectiveness, or maintenance failures.
• The company must seek stockholder approval by October 31, 2025, for the issuance of more than 19.99% of its outstanding common stock, with subsequent meetings every 75 days if not obtained.
• The company must maintain at least $8,400,000 in unencumbered, unrestricted cash and cash equivalents.
• GP Nurmenkari Inc. is acting as the sole placement agent, receiving an 8.0% cash fee of gross proceeds, a $10,000 non-accountable expense, and warrants for 8.0% of common stock shares sold to GPN Investors.

Sentiment

Score: 3

Explanation: While the capital raise provides needed funds and is supported by existing investors, the terms are highly unfavorable and dilutive to common shareholders, indicating a high cost of capital and potential financial distress. The high dividend rate, significant redemption premiums, and full-ratchet anti-dilution on warrants suggest a company in a weak bargaining position.

Positives

• Secured $7 million in capital, strengthening the balance sheet.
• Financing led by existing investors, indicating continued support and confidence.
• Funds are allocated for general corporate purposes and strategic alternatives, potentially enabling future growth initiatives.

Negatives

• The terms of the preferred stock and warrants are highly dilutive, with up to 14,000,000 shares potentially issuable compared to approximately 6.8 million outstanding common shares.
• The 7% cash dividend on preferred stock represents a high ongoing cost of capital, escalating to 15% upon a 'Triggering Event'.
• Warrants include a 'full ratchet' anti-dilution provision, which is highly unfavorable to existing common shareholders as it adjusts the exercise price downwards if the company issues shares at a lower price.
• High redemption premiums (125% for Triggering Event, 300% for Involuntary Change of Control, 106% for Maturity) mean the company will pay a substantial premium to redeem these securities.
• The company is subject to a restrictive covenant requiring it to maintain at least $8,400,000 in unencumbered, unrestricted cash.
• The 8% placement agent fee (cash and warrants) is a significant cost for securing the capital.

Risks

• Failure to obtain stockholder approval for the issuance of more than 19.99% of outstanding common stock could lead to limitations on conversions or further penalties.
• Company's failure to timely deliver shares upon conversion or exercise of securities could result in significant cash penalties (2% of product of shares not issued and trading price).
• Company's failure to maintain an effective registration statement for resale of the securities could incur liquidated damages (2% of purchase price every 30 days).
• Breach of covenants related to indebtedness, liens, restricted payments, asset transfers, or the required cash minimum could trigger redemption rights at a premium.
• Potential delisting or suspension of common stock from Nasdaq due to non-compliance with listing standards or other issues.
• Any final judgment or judgments for the payment of money aggregating in excess of $250,000 not bonded, discharged, settled, or stayed could constitute a Triggering Event.
• Default under or acceleration of at least $250,000 of Indebtedness of the Company or its Subsidiaries could constitute a Triggering Event.

Future Outlook

The company expects to use the net proceeds from the private placement for general corporate purposes and working capital. Management believes this financing will strengthen the balance sheet, enhance shareholder value, and enable the pursuit of strategic alternatives to maximize long-term returns for stockholders.

Management Comments

• "This financing, priced at a premium to our current market price and led by our existing investors, reflects strong confidence in PharmaCytes future."
• "It meaningfully strengthens our balance sheet, positions us to enhance shareholder value, and enables us to continue pursuing strategic alternatives that we believe can maximize long-term returns for our stockholders."

Industry Context

This private placement provides capital to a biotech company, which often requires significant funding for research and development and operational expenses. The involvement of existing investors suggests continued support, but the terms (high dividend, redemption premiums, full ratchet anti-dilution on warrants) indicate a potentially high cost of capital, common for companies in early or challenging stages of development, or those with limited access to traditional financing. The need for stockholder approval for significant dilution also highlights regulatory constraints for Nasdaq-listed companies.

Comparison to Industry Standards

• The 7% cash dividend on preferred stock, escalating to 15% upon a Triggering Event, is a high cost of capital, typically seen in distressed companies or those with limited financing options, significantly above standard corporate bond yields or typical preferred stock dividends for stable companies.
• The 125% (or 300% for involuntary change of control) redemption premium on Triggering Events and 106% on Maturity Date for preferred stock are substantial, indicating a strong preference for capital protection and return for investors, often higher than typical for less risky investments.
• The 'full ratchet' anti-dilution protection on warrants is highly investor-friendly and very dilutive to existing common shareholders, as it adjusts the exercise price downwards if the company issues shares at a lower price, effectively giving new investors a better deal at the expense of existing ones. This is more aggressive than weighted-average anti-dilution often seen in less risky private placements.
• The requirement to maintain an $8.4 million cash minimum is a restrictive covenant, common in debt-like preferred equity structures, ensuring liquidity for the preferred shareholders but potentially limiting operational flexibility.
• The 8% placement agent fee (cash and warrants) is on the higher end for private placements, reflecting the perceived risk or difficulty in securing this financing.

Corporate Governance

Related Party Transactions

• Existing investors are leading the $7 million capital raise.
• GP Nurmenkari Inc. is acting as the sole placement agent and will receive fees and warrants as compensation.

Stakeholder Impact

• Shareholders: Significant potential for dilution from the conversion of preferred stock and exercise of warrants. Common stock value could be negatively impacted by the dilutive terms and high cost of capital.
• Creditors: The new preferred stock has dividend and redemption preferences, which could impact the company's ability to service other debts, especially if Triggering Events occur. The cash minimum covenant might offer some comfort regarding liquidity.
• Management: Gains capital for general corporate purposes and strategic alternatives, but faces restrictive covenants and high penalties for non-compliance.

Next Steps

• Closing of the Private Placement expected on August 19, 2025.
• Company to file a resale registration statement (Form S-3) for 150% of Conversion Shares and Warrant Shares within 30 calendar days of August 17, 2025.
• Company to seek stockholder approval for issuance of more than 19.99% of outstanding common stock by October 31, 2025, with subsequent meetings every 75 days if not obtained.
• Company to pay quarterly cash dividends on preferred stock starting October 1, 2025.

Key Dates

Recommendation

The terms of this capital raise are highly unfavorable for existing common shareholders, indicating a company in a precarious financial position. The significant potential for dilution (14 million shares from preferred and warrants vs. ~6.8 million outstanding common shares), the high 7% cash dividend on preferred stock (escalating to 15% on default), and the extremely dilutive 'full ratchet' anti-dilution on warrants suggest a substantial transfer of value from common shareholders to the new investors. The high redemption premiums further exacerbate the cost of this capital. While the raise provides immediate liquidity, the long-term implications of these terms, coupled with the company's need for such expensive financing, point to significant downside risk for common stock. Investors should consider exiting their positions to avoid further value erosion.

Keywords

PharmaCyte Biotech, PMCB, Private Placement, Convertible Preferred Stock, Warrants, Capital Raise, SEC Filing, Nasdaq, Biotech, Financing, Dilution, Investor Relations